“We recommend doing the spot cautery,” says Andrew Higgins, MD.
In this video, Andrew Higgins, MD, discusses how the combination of Aquablation therapy and electrocautery has already shown promise and will be researched further to continue to advance BPH treatment. “Prostate Aquablation: 2 years of perioperative outcomes,” presented recently at the 2021 American Urological Association annual meeting. Higgins is a urology resident at Einstein Healthcare Network, Philadelphia, Pennsylvania.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.